Brief: Orphazyme A/S Anticipates A Loss From Continuing Operations In Range Of DKK 40 Million - 45 Million

Strategic Partners A/S

25/09/2022 21:13

Sept 25 (Reuters) - Orphazyme A/S  ORPHA.CO :
    * HAS DECIDED TO ADJUST ITS OUTLOOK FOR 2022
    * CHANGE IS DRIVEN BY SEPARATION OF ACTIVITIES INTO
CONTINUING AND
DISCONTINUED OPERATIONS
    * EXPECT TO END 2022 WITH MORE THAN DKK 30 MILLION IN CASH
AND
EQUIVALENTS
    * FOR FULL-YEAR 2022, WE ANTICIPATE A LOSS FROM CONTINUING
OPERATIONS IN RANGE DKK 40 MILLION - 45 MILLION
    * FOR FULL-YEAR 2022, WE ANTICIPATE A POSITIVE RESULT FROM
DISCONT
OPERATIONS RELATING TO THE SALE OF ASSETS TO KEMPHARM OF DKK
87.4 MILLION

Source text for Eikon:  ID:nGNE9ZWqDc 
Further company coverage:  ORPHA.CO 
 ((Reuters.Briefs@thomsonreuters.com;))